Korea National Enterprise for Clinical Trials (KoNECT) and DIA (Drug Information Association), based in Washington, D.C., have signed a Memorandum of Understanding (MoU) to establish a cooperative relationship and explore collaboration in development of training, education and knowledge exchange opportunities.

Both organizations have an interest in delivering educational offerings through classroom and on-line training courses, along with additional opportunities to further develop and advance innovations in therapeutic product development.

KoNECT was established in April as a nonprofit foundation by the Korean Ministry of Health and Welfare for furthering development of clinical trial infrastructure and capability, to establish Korea as a global clinical trial hub and preferred partner for drug development in the Asia Pacific region, as the continuum of the 1^st KoNECT established in December 2007.

DIA was established in 1964 as a nonprofit neutral forum to increase communication and collaboration in drug development in order to improve product safety and efficacy and to advance therapeutic successes.

Dr. Deborah Chee, KoNECT’s president, said, “We are delighted to sign an MOU with DIA, reinforcing bilateral collaboration between DIA and Korea, with a common ultimate goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients. Together with DIA, KoNECT hopes to provide high-quality training to Korean clinical trial professionals and in the process, help to advance their competency.”

Barbara Lopez Kunz, DIA’s global chief executive, said, “DIA is excited about the possibility of expanding our impact in Korea. This collaboration with KoNECT provides us with access to a network of partners and the opportunity to make a positive difference in helping to bring safe and effective health therapies to the Korean market and to the patients served.”